Case Presentation: A 64-Year-Old Woman With HER2+ mCRC

Kristen K. Ciombor, MD, MSCI, gives an overview of the current treatment landscape for patients with metastatic colorectal cancer.

Geraldine O’Sullivan Coyne, MD, PhD, MRCPI, discusses how the START center may expand access to novel therapies for patients who reside in a community setting.

Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.